Key facts
- Aeovian Pharmaceuticals’s last known valuation is $172.0M (Dec 2025).
- It has raised $143.2M across 3 recorded rounds; the latest was Later Stage VC ($55.0M) in Nov 2025.
- Notable investors include FJ Labs, United States Department of War, TA Ventures, b2venture, Foresite Capital — 22 tracked in total.
- Aeovian Pharmaceuticals has filed 3 Form Ds with the SEC since 2019, most recently Dec 2025 ($55.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Aeovian Pharmaceuticals
Funding rounds
3 roundsAbout Aeovian Pharmaceuticals
Developer of biotechnology therapies intended to address inflammatory and degenerative diseases. The company's platform utilizes small molecule therapeutics to target key cellular pathways involved in inflammation and disease progression, incorporating advanced drug design, precision targeting, and optimized pharmacokinetics, enabling the healthcare industry to develop more effective treatments with improved safety profiles for patients suffering from chronic and debilitating conditions.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2012
- Employees
- 8
- Website
- aeovian.com/
- Ownership
- Privately Held (backing)
Aeovian Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aeovian Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aeovian Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.